Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stichting Sanquin Bloedvoorziening
Original Assignee
Stichting Sanquin Bloedvoorziening
Cornelis Erik Hack
Walter Wuillemin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stichting Sanquin Bloedvoorziening, Cornelis Erik Hack, Walter WuilleminfiledCriticalStichting Sanquin Bloedvoorziening
Priority claimed from PCT/NL1996/000488external-prioritypatent/WO1997022347A1/fr
Publication of CA2239787A1publicationCriticalpatent/CA2239787A1/fr
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
CA 22397871995-12-181996-12-18Potentialisation des proprietes d'inhibition du complement et de la coagulation d'un inhibiteur de c1
AbandonedCA2239787A1
(fr)
Supranormal antithrombin III levels induced by concentrate administration are ineffective in quenching thrombin generation in acute promyelocytic leukemia
A supersulfated low-molecular-weight heparin (IK-SSH) increases plasma levels of free and total tissue factor pathway inhibitor after intravenous and subcutaneous administration in humans